Status of plasma nitric oxide and non-enzymatic antioxidants before and after antipsychotic treatment in Nigerian patients with schizophrenia

Journal of Research in Medical Sciences

Volumn 14, Issue 1, 2009, Pages 37-42

  Arinola, O G ^a   Idonije, O B ^b  

^a UNIVERSITY OF IBADAN   (Nigeria)

^b AMBROSE ALLI UNIVERSITY   (Nigeria)

Author keywords

Antioxidant defense system; Antioxidant status; Oxidative stress; Schizophrenia

Indexed keywords

CERULOPLASMIN; COPPER; IRON; MANGANESE; NEUROLEPTIC AGENT; NITRIC OXIDE; SELENIUM; TRACE METAL; ZINC;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BLOOD ANALYSIS; CERULOPLASMIN BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; COPPER BLOOD LEVEL; DOSE RESPONSE; ENZYME BLOOD LEVEL; FEMALE; HUMAN; IMMUNODIFFUSION; MALE; NIGERIA; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT SELECTION; SCHIZOPHRENIA; TRACE METAL BLOOD LEVEL; ZINC BLOOD LEVEL;

EID: 63249129477     PISSN: 17351995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004; 2:13.
2. Akyol O, Zoroglu SS, Armutcu F, Sahin S, Gurel A. Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In Vivo 2004; 18(3):377-90.
3. Smythies J. Recent advances in the neurobiology of schizophrenia. German J Psychiatry 1998; 1(2):24-40.
4. Lorrain DS, Hull EM. Nitric oxide increases dopamine and serotonin release in the medial preoptic area. Neuroreport 1993; 5(1):87-9.
5. Karson CN, Griffin WS, Mrak RE, Husain M, Dawson TM, Snyder SH, et al. Nitric oxide synthase (NOS) in schizophrenia: increases in cerebellar vermis. Mol Chem Neuropathol 1996; 27(3):275-84.
6. Das I, Khan NS, Puri BK, Sooranna SR, de Belleroche J, Hirsch SR. Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem Biophys Res Commun 1995; 212(2):375-80.
7. Herken H, Uz E, Ozyurt H, Akyol O. Red blood cell nitric oxide levels in patients with schizophrenia. Schizophr Res 2001; 52(3):289-90.
8. Nakaki T, Mishima A, Fujii T, Suzuki E, Shintani F. Nitric oxide and neurodegenerative diseases. Pharmacol Toxicol 1997; 3:157-63.
9. Yao JK, Reddy R, van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 1998; 80(1):29-39.
10. Yao JK, Reddy R, McElhinny LG, van Kammen DP. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 1998; 32(1):1-8.
11. Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 1996; 19(1):1-17.
12. Bast A, Haenen GR, Doelman CJ. Oxidants and antioxidants: state of the art. Am J Med 1991; 91(3C):2S-13S.
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-IV-TR. 4th ed. New York: American Psychiatric Publishing Inc; 2000.
14. Arinola G, Arowojolu A, Bamgboye A, Akinwale A, Adeniyi A. Serum concentrations of immunoglobulins and acute phase proteins in Nigerian women with preeclampsia. Reprod Biol 2006; 6(3):265-74.
15. Laudanska E, Gwozdz A, Brudel G, Rajchert J. [Evaluation of Griess reagent and TTC tests in obstetrics]. Ginekol Pol 1970; 41(8):857-62.
16. Kaneko JJ. Clinical biochemistry of domestic animals. 4 Sub ed. New York: Academic Pr; 1989. p. 932.
17. Srivastava N, Barthwal MK, Dalal PK, Agarwal AK, Nag D, Srimal RC, et al. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology (Berl) 2001; 158(2):140-5.
18. Glen AI, Glen EM, Horrobin DF, Vaddadi KS, Spellman M, Morse-Fisher N, et al. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr Res 1994; 12(1):53-61.
19. Strunecka A, Ripova D. What can the investigation of phosphoinositide signaling system in platelets of schizophrenic patients tell us? Prostaglandins Leukot Essent Fatty Acids 1999; 61(1):1-5.
20. Weiser M, Levkowitch Y, Neuman M, Yehuda S. Decrease of serum iron in acutely psychotic schizophrenic patients. Int J Neurosci 1994; 78(1,2):49-52.
21. Yanik M, Kocyigit A, Tutkun H, Vural H, Herken H. Plasma manganese, selenium, zinc, copper, and iron concentrations in patients with schizophrenia. Biol Trace Elem Res 2004; 98(2):109-17.
22. Pavlovic D, Tamburic V, Stojanovic I, Kocic G, Jevtovic T, Dordevic V. Oxidative stress as marker of positive symptoms in schizophrenia. Medicine and Biology 2002; 9(2):157-61.
23. Johnson S. Micronutrient accumulation and depletion in schizophrenia, epilepsy, autism and Parkinson's disease? Med Hypotheses 2001; 56(5):641-5.
24. Brown JS, Jr. Role of selenium and other trace elements in the geography of schizophrenia. Schizophr Bull 1994; 20(2):387-98.
25. Dadheech G, Mishra S, Gautam SH, Sharma P. Evaluation of antioxidant deficit in schizophrenia. Indian J Psychiatry 2008; 50(1):16-20.
26. Suzuki E, Nakaki T, Nakamura M, Miyaoka H. Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia. J Psychiatry Neurosci 2003; 28(4):288-92.
27. Davies IJT. The clinical significance of the essential biological metals. Springfield, Illinois: C.C.Thomas; 1972. p. 74.
28. Dakhale GN, Khanzode SD, Khanzode SS, Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology (Berl) 2005; 182(4):494-8.